On the leading edge of Personalized Medicine, Big Data Analytics and Biotech R&D for ~20 years, Iris is acting CSO of Amide and advises other biotech in her field of expertise. She has held leadership positions in, or consulted for top Big Pharma (GSK, Eli Lily, Takeda and Teva as VP, Head of Early Stage Clinical Development), startup (CAMP4 as Chief Scientific Officer) and consultancies (Cabernet and GROSS Advantage as cofounder). She specializes in leveraging high dimensional genomic insights and eHealth as engines of therapeutic discovery, development and lifecycle management across a wide range of modalities and therapeutic areas. Iris serves as SAB member of Eleven therapeutics, BC Platforms, Tipa biobank and CGRP Dx. She earned her B.Sc. in medicine at the Technion, and a Ph.D. in medicine, population genomics and pharmacogenetics from the Technion, co-mentored with the Weizmann Institute. Her post-doc fellowship in personalized medicine and population genomics was conducted at Duke university.